The global pharmaceutical market is approximately US$ 825 billion. While we evaluate the volume of the market, it is also important to know that which aspect of the drug response this market size refers to. The term drug response includes two facets: drug effectiveness (effi cacy) and drug side effects. It is estimated that, on average, as much as 40% of the medicines that individuals take every day are not effective. In fact, for certain medications the estimate of non effectiveness is well over 50%. This would mean that close to US$ 400 billion are effectively wasted. While referring to specifi c classes of drugs, a conservative estimate indicates that 15-35% of patients have an adequate or no response to β-blockers; 7-28% of patients have an adequate or no response to angiotensin-converting enzyme inhibitors; 9-23% of patients respond inadequately to selective serotonin reuptake inhibitors; 20-50% of patients have an adequate or no response to tricyclic antidepressants, 10-20% of patients do not initially respond to antipsychotic therapy, and an additional 20-30% who do respond early on eventually relapse and some develop serious side effects. [1] In more than 91.2% of drug treatments approved in the USA in the last decade, the teratogenic risks in human pregnancy remain undetermined. [2] Evaluating the side effects of the drugs would further add burden to the economy of drug response. These observations raise serious apprehensions about how India should address its health benefi t concerns. India occupies 20% of the world population, but shares only 2% of the global pharmaceutical market and that too for generic drugs. This would mean that newer and probably safer drugs are out of reach of common Indians. Adverse drug reporting is also not a common practice in most of the clinical establishments in India. As early as 1892, Sir William Osler made an observation that "If it were not for the great variability among individuals, medicine might as well be a science and not an art." Today the science behind this art is being dissected out by understanding the pharmacogenomic variability. In a recent observation it has been very clearly demonstrated that how genomic information can yield useful and clinically relevant information for individual patients. [3] Now, it has been established that the economic burden of drug response can be drastically minimized by genomic technologies. [4] Realizing the potential of pharmacogenomic profi ling, the top 10 global pharmaceutical giants created a public SNP database as early as 1999, through an industry-funded industry academia US nonprofi t organization and named it "The SNP Consortium Ltd." The objective of this consortium was to develop a high-density, high-quality map with shared fi nancial risks and less duplication of effort. [5] The consortium initiated the program with a budget of US$ 48 million and has already earned back their investment by providing access to nonpartners of the consortium through their database. This joint venture became a model for streamlining the process of drug response monitoring S2 in clinical trials. Pharmacogenomics Knowledgebase (www.PharmGKB.org) initiated a mission to collect, encode, and disseminate knowledge about the impact of human genetic variations on drug response. Subsequently, FDA in 2005 incorporated the guidelines for genomic data submission for drug approval. Presently, the genomic data submission for drug approval is voluntary but with increasing awareness very soon this would be mandatory. Today there are several FDA approved drugs with pharmacogenomic information in their labels (www.fda.gov/Drugs/ScienceResearch/ ResearchAreas/Pharmacogenetics/ucm083378.htm).
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As early as 1892, Sir William Osler made an observation that "If it were not for the great variability among individuals, medicine might as well be a science and not an art." Today the science behind this art is being dissected out by understanding the pharmacogenomic variability. In a recent observation it has been very clearly demonstrated that how genomic information can yield useful and clinically relevant information for individual patients. [3] Now, it has been established that the economic burden of drug response can be drastically minimized by genomic technologies. [4] Realizing the potential of pharmacogenomic profi ling, the top 10 global pharmaceutical giants created a public SNP database as early as 1999, through an industry-funded industry academia US nonprofi t organization and named it "The SNP Consortium Ltd." The objective of this consortium was to develop a high-density, high-quality map with shared fi nancial risks and less duplication of effort. [5] The Based on patient's genotype, gender, age, family, and medical history, more than 650 drug-related variants have been identifi ed for their clinical relevance. [6] With rapid growth of IT infrastructure and penetration of Internet technologies, these information are fast reaching the Indian household. This may drastically change the practice of medicine in coming years and may cause concern for practitioners for being unaware of the developments. Since Indians live in a strong emotionally and culturally driven society, implications can be wide ranging.
The country should debate on how India can channel its limited fi nancial resources, knowing that the drug discovery programs and the drug response monitoring programs can be of huge economic liabilities. The challenges are further aggravated by the genetic diversity of the resources for both, the natural product drug discovery programs and drug response monitoring programs. Knowing that the drug discovery programs are full of uncertainties, [7] in contrast, the drug response monitoring is always a result-oriented initiative.
Interestingly, India's pharmaceutical market, mostly deals with generic drugs, therefore, it further strengthens the view that drug response monitoring program based on pharmacogenomic profi ling of Indian populations is ideal for having a safer response to medications. For pharmaceutical companies worldwide, India is not only a potentially huge market for drug therapeutics but is also a repository of important human genetic diversity.
Understanding this diversity is valuable because it better defi nes those population subgroups that will benefi t more from a particular drug than others, and allows the detection of side-effects that might not be seen in populations that are mainly Caucasian. On a similar note, it has been argued that the blockbuster analgesic drug Vioxx (rofecoxib) which was withdrawn from the market because of its cardiovascular complications in those who took it for more than 18 months could have been put to use in populations with a safer pharmacogenomic background. [8] Historical gene fl ow into India has also contributed to a considerable obliteration of genetic histories of contemporary populations. [9] A recent study provided strong evidence for two genetically divergent ancient populations that are ancestral to most present day Indians. One, the "Ancestral North Indians" (ANI), is genetically close to Middle Easterners, Central Asians, and Europeans, whereas the other, the "Ancestral South Indians" (ASI), is as distinct from ANI and East Asians as they are from each other. [10] Demic diffusion of the ancestral local progressive communities with the migrant communities has been hypothesized for the process of admixtures among Dravidian communities. [11] India conceptualized its first consortium based human genome variation database with an objective to catalog the variations in nearly 1000 candidate genes related to diseases and drug responses for predictive marker discovery, founder identifi cation and also to address questions related to ethnic diversity, migrations, extent, and relatedness with other world population. [12] The knowledge gained from these studies and several individual-based studies can provide tremendous impetus to understanding of therapeutic response to drugs that Indians routinely take.
India is far behind in addressing the foreseeable challenge of drug response monitoring or even on 
